Quick Answer
HUTCHMED (China) Ltd reported Cash and Equivalents of $71.33 million for fiscal year 2025.
HUTCHMED (China) Ltd Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $71.33M | -53.7% |
| 2024 | $153.96M | -45.7% |
| 2023 | $283.59M | -9.5% |
| 2022 | $313.28M | -17.0% |
| 2021 | $377.54M | +60.2% |
| 2020 | $235.63M | +94.5% |
| 2019 | $121.16M | +40.8% |
| 2018 | $86.04M | +0.9% |
| 2017 | $85.27M | +7.3% |
| 2016 | $79.43M | +148.7% |
| 2015 | $31.94M | -18.0% |
| 2014 | $38.95M | -16.9% |
| 2013 | $46.86M | — |
- HUTCHMED (China) Ltd showed a decrease of -53.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, HUTCHMED (China) Ltd’s cash and equivalents has grown by 52.2% (from $46.86 million to $71.33 million).
- The most recent figure is from HUTCHMED (China) Ltd’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: